These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9525123)

  • 21. Immunization against hepatitis A during an outbreak in a Jewish Orthodox community--Quebec, 1997-1998.
    Deshaies D; Dion R; Valiquette L; Auger N
    Can Commun Dis Rep; 1998 Sep; 24(18):145-51. PubMed ID: 9780447
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine.
    Dumas R; Forrat R; Lang J; Farinelli T; Loutan L
    Adv Ther; 1997; 14(4):160-7. PubMed ID: 10174195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vaccination against hepatitis A].
    Zamir D; Zamir H; Weiner P
    Harefuah; 1998 Aug; 135(3-4):114-8. PubMed ID: 9885656
    [No Abstract]   [Full Text] [Related]  

  • 24. Who should receive hepatitis A vaccine?
    Brewer MA; Edwards KM; Decker MD
    Pediatr Infect Dis J; 1995 Apr; 14(4):258-60. PubMed ID: 7603804
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
    Kanra G; Yalçin SS; Ceyhan M; Yurdakök K
    Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis A-vaccines: a comparison between three methods of antigen determination.
    Burkhardt F; Glück R; Finkel-Jimenez B; Brantschen S
    Dev Biol Stand; 1996; 86():129-35. PubMed ID: 8785942
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.
    Bovier PA; Bock J; Loutan L; Farinelli T; Glueck R; Herzog C
    J Med Virol; 2002 Dec; 68(4):489-93. PubMed ID: 12376955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of hepatitis A by Havrix: a review.
    Van Herck K; Van Damme P
    Expert Rev Vaccines; 2005 Aug; 4(4):459-71. PubMed ID: 16117704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial.
    Mayorga Pérez O; Herzog C; Zellmeyer M; Loáisiga A; Frösner G; Egger M
    J Infect Dis; 2003 Sep; 188(5):671-7. PubMed ID: 12934183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative antigenic activity of the hepatitis A inactivated vaccine among military personnel].
    Shumilov VI; Shevtsov VA; Lobastov SP; Salmina TA; Shervarli VI; Vardanian NV; Nikolaeva EI
    Voen Med Zh; 2004 Jan; 325(1):62-5. PubMed ID: 15038272
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatitis A: the vaccine dividend.
    Dienstag JL
    J Infect Dis; 2008 May; 197(9):1220-2. PubMed ID: 18422432
    [No Abstract]   [Full Text] [Related]  

  • 33. Hepatitis A vaccine gains marketing approval.
    Am J Health Syst Pharm; 1995 May; 52(9):926, 931. PubMed ID: 7641029
    [No Abstract]   [Full Text] [Related]  

  • 34. Release potency tests of hepatitis vaccines.
    Descamps J; Mary A; Rommel E; Anhoury ML; De Neys R; Duchêne M
    Dev Biol Stand; 1999; 101():289-94. PubMed ID: 10566803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of poly(ethylene glycol) precipitation of hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine.
    Hagen AJ; Oliver CN; Sitrin RD
    Biotechnol Prog; 1996; 12(3):406-12. PubMed ID: 8652125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Studies on re-immunization with live attenuated hepatitis A vaccine].
    Liu Y; Xu Z; Ouyang P
    Zhonghua Yu Fang Yi Xue Za Zhi; 1998 May; 32(3):162-4. PubMed ID: 10322791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The vaccinal prevention of viral hepatitis A in military groups].
    Sabanin IuV; Rikhter VV; El'nikov VS
    Voen Med Zh; 1998 Aug; 319(8):58-60. PubMed ID: 9793452
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatitis A vaccines.
    Shahidah KN
    Med J Malaysia; 2005 Jul; 60 Suppl B():112-5. PubMed ID: 16108190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.
    Ambrosch F; Finkel B; Herzog C; Koren A; Kollaritsch H
    Infection; 2004 Jun; 32(3):149-52. PubMed ID: 15188074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunogenicity and efficacy trials of live attenuated hepatitis A vaccines].
    Xu Z; Li R; Meng Z
    Zhonghua Yi Xue Za Zhi; 1998 Apr; 78(4):254-6. PubMed ID: 10923477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.